San­thera lays out op­tions in bid for com­mer­cial­iza­tion funds; Swiss biotech’s Covid work nar­rows

As San­thera waits for the FDA’s sig­nal on its rolling NDA sub­mis­sion, the pen­ny stock biotech is look­ing to se­cure more fund­ing.

The Swiss pen­ny stock biotech an­nounced the up­com­ing meet­ing Fri­day morn­ing, sched­uled for No­vem­ber 29, say­ing that it is plan­ning on ad­vanc­ing its prepa­ra­tions to launch its can­di­date va­morolone for Duchenne mus­cu­lar dy­s­tro­phy, or DMD. But in or­der to do that, it needs mon­ey.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER